research Signal Mining for Non-Bleeding Adverse Event in Novel Oral Anticoagulants: A Pharmacovigilance Study Based on the FAERS Database
Different oral anticoagulants cause various non-bleeding side effects, so careful monitoring is needed.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research A Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Effectiveness of Botanically Derived Inhibitors of 5-α-Reductase in the Treatment of Androgenetic Alopecia
Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.
research Ruolo dei neurosteroidi nella modulazione dopaminergica
Neurosteroids help control dopamine responses in the brain.
research Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice
Dutasteride may protect the brain in early Parkinson's disease.
research Aqueous Extract of Bacopa procumbens and the NAPEL Formulation Mitigate MPTP-Induced Neurotoxicity via Nrf2/HSF1/HIF-1α Signaling in a Parkinson’s Disease Model
Bacopa procumbens extract may help protect the brain in Parkinson's disease.
research (PNM-35) Recurrent priapism in a sickle cell disease patient treated with gonadotropin-releasing hormone (GnRH) agonists drugs: a case report
GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.
research A New Era of 5α-Reductase Inhibitors for Androgenetic Alopecia
New drug dutasteride effectively treats hair loss, but use cautiously due to potential sexual side effects.
research The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
research Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier
New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
research 42134 Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-naïve Patients With Psoriatic Arthritis (PsA)
Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.